Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bjh.12584 http://scihub22266oqcxt.onion/10.1111/bjh.12584 C5127390!5127390!24117210     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Haematol 2014 ; 164 (1): 24-38 Nephropedia Template TP {{tp|p=24117210|t=2014. How I Treat Children and Adolescents with Acute Promyelocytic Leukaemia |pdf=|usr=}}{{24117210}} gab.com Text How I Treat Children and Adolescents with Acute Promyelocytic Leukaemia JO: Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=24117210 #FOAvip Acute promyelocytic leukaemia (APL) is a rare subtype of acute myeloid leukaemia. The outcome of paediatric APL has improved substantially over the past 20 years; cure rates above 80% are expected when all-trans retinoic acid (ATRA) is given with anthracycline-based regimens. The presenting features of paediatric APL may include severe bleeding and thrombotic complications, which contribute to the high early death rate. The incidence of leucocytosis and the microgranular subtype is greater in paediatric than adult APL, and children experience greater ATRA-related toxicity. It is crucial to begin ATRA therapy and intensive platelet and fibrinogen replacement on first suspicion of APL. Recent risk-adapted therapeutic trials have shown that patients at greater risk of relapse benefit from the introduction of high-dose cytarabine during consolidation. Combination therapy with ATRA and arsenic trioxide provides very effective frontline treatment and may reduce the need for subsequent anthracycline therapy. Twit Text FOAVip How I Treat Children and Adolescents with Acute Promyelocytic Leukaemia ????Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=24117210 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24117210 #FOAvip English Wikipedia <ref>{{Cite pmid|24117210}}</ref> How I Treat Children and Adolescents with Acute Promyelocytic Leukaemia #MMPMID24117210 Abla O; Ribeiro RC Br J Haematol 2014[Jan]; 164 (1): 24-38 PMID24117210show ga Acute promyelocytic leukaemia (APL) is a rare subtype of acute myeloid leukaemia. The outcome of paediatric APL has improved substantially over the past 20 years; cure rates above 80% are expected when all-trans retinoic acid (ATRA) is given with anthracycline-based regimens. The presenting features of paediatric APL may include severe bleeding and thrombotic complications, which contribute to the high early death rate. The incidence of leucocytosis and the microgranular subtype is greater in paediatric than adult APL, and children experience greater ATRA-related toxicity. It is crucial to begin ATRA therapy and intensive platelet and fibrinogen replacement on first suspicion of APL. Recent risk-adapted therapeutic trials have shown that patients at greater risk of relapse benefit from the introduction of high-dose cytarabine during consolidation. Combination therapy with ATRA and arsenic trioxide provides very effective frontline treatment and may reduce the need for subsequent anthracycline therapy. äHow I Treat Children and Adolescents with Acute Promyelocytic Leukaemi(epmc).pdf DeepDyve Pubget Overpricing